Karyopharm Therapeutics Inc (NASDAQ:KPTI) is gearing up to unveil its Q2 2025 earnings on August 11, 2025. Analysts anticipate the Q2 2025 revenue to be around $36.77 million, with an expected earnings per share of -$4.12. Looking ahead to the full year 2025, revenue projections stand at $145.36 million, while earnings per share are estimated to be -$12.18. For a more comprehensive breakdown of estimates, interested parties can refer to the Forecast page.
Recent trends in estimates for Karyopharm Therapeutics Inc (NASDAQ:KPTI) reveal a slight decline in revenue expectations for both 2025 and 2026. Over the past 90 days, revenue estimates have shifted from $149.32 million to $145.36 million for 2025 and from $173.64 million to $164.12 million for 2026. On the flip side, earnings estimates have shown a positive trajectory, moving from -$13.81 per share to -$12.18 per share for 2025 and from -$9.55 per share to -$7.52 per share for 2026 during the same period.
Delving into the reported history of Karyopharm Therapeutics Inc (NASDAQ:KPTI), the previous quarter’s results for 2025-03-31 depicted actual revenue of $30.02 million, falling short of analysts’ expectations by 14.83%. However, the company outperformed earnings projections, with actual earnings per share at -$2.77, surpassing estimates by 33.45%. Following this announcement, Karyopharm Therapeutics Inc experienced a 20% decline in its stock price within a single trading day.
Analysts’ one-year price targets suggest an optimistic outlook for Karyopharm Therapeutics Inc (NASDAQ:KPTI), with an average target price of $22.50, ranging from a high estimate of $42.00 to a low estimate of $8.00. This average target implies a potential upside of 466.75% from the current stock price of $3.97. Additionally, GuruFocus estimates a GF Value of $17.01 for the company in one year, indicating a potential upside of 328.46% from the current price.
Considering the consensus recommendation from 7 brokerage firms, Karyopharm Therapeutics Inc (NASDAQ:KPTI) currently holds an average brokerage recommendation of 2.0, signaling an “Outperform” status. This rating scale ranges from 1 to 5, where 1 denotes a strong buy and 5 indicates a sell recommendation. It is crucial to note that this analysis, provided by GuruFocus, serves as general insights based on historical data and analyst forecasts, and does not constitute personalized financial advice.
Key Takeaways:
– Karyopharm Therapeutics Inc’s Q2 2025 earnings report is highly anticipated, with revenue and earnings per share estimates in focus.
– Recent trends indicate a minor decline in revenue forecasts for 2025 and 2026, alongside an improvement in earnings expectations.
– The company’s stock price reaction to previous quarterly results underscores the market’s sensitivity to performance metrics.
– Analysts’ price targets and consensus recommendations paint a positive outlook for Karyopharm Therapeutics Inc’s future performance.
Read more on finance.yahoo.com